Amelioration of cisplatin-induced nephrotoxicity in peroxiredoxin I-deficient mice

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 503-509

  Okada, Kosuke ^a   Ma, Dongmei ^a   Warabi, Eiji ^a   Morito, Naoki ^a   Akiyama, Kentaro ^a   Murata, Yasuhiro ^a   Yamagata, Kenji ^a   Bukawa, Hiroki ^a   Shoda, Junichi ^a   Ishii, Tetsuro ^a   Yanagawa, Toru ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

c Myc; Cisplatin; Mrp; Nephrotoxicity; Peroxiredoxin I

Indexed keywords

CISPLATIN; MYC PROTEIN; PEROXIREDOXIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HISTOPATHOLOGY; IN VITRO STUDY; KIDNEY CLEARANCE; KIDNEY INJURY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PEROXIREDOXINS;

EID: 84874105582     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2046-0     Document Type: Article

References (28)

1. Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ, Manautou JE (2008) Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology 250:82-88
2. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD (2010) Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 335:2-12
3. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302
4. Boulikas T, Vougiouka M (2004) Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 11:559-595
5. Boyer JL (2005) Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129:735-740
6. Butterfield LH, Merino A, Golub SH, Shau H (1999) From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid Redox Signal 1:385-402
7. Chae HZ, Kim HJ, Kang SW, Rhee SG (1999) Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract 45:101-112
8. Chang TS, Jeong W, Choi SY, Yu S, Kang SW, Rhee SG (2002) Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation. J Biol Chem 277:25370-25376
9. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
10. Daugaard G, Abildgaard U (1989) Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol 25:1-9
11. Demeule M, Brossard M, Beliveau R (1999) Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am J Physiol 277:F832-F840
12. Egler RA, Fernandes E, Rothermund K, Sereika S, de Souza-Pinto N, Jaruga P, Dizdaroglu M, Prochownik EV (2005) Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 24:8038-8050
13. Hofmann B, Hecht HJ, Flohe L (2002) Peroxiredoxins. Biol Chem 383:347-364
14. Huang Q, Dunn RT 2nd, Jayadev S, DiSorbo O, Pack FD, Farr SB, Stoll RE, Blanchard KT (2001) Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci 63:196-207
15. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S, Yamamoto M (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275:16023-16029
16. Ishii T, Yamada M, Sato H, Matsue M, Taketani S, Nakayama K, Sugita Y, Bannai S (1993) Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. J Biol Chem 268:18633-18636
17. Kang KW, Im YB, Go WJ, Han HK (2009) c-Myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells. Mol Pharm 6:627-633
18. Ma D, Warabi E, Yanagawa T, Kimura S, Harada H, Yamagata K, Ishii T (2009) Peroxiredoxin I plays a protective role against cisplatin cytotoxicity through mitogen activated kinase signals. Oral Oncol 45:1037-1043
19. Okada K, Shoda J, Kano M, Suzuki S, Ohtake N, Yamamoto M, Takahashi H, Utsunomiya H, Oda K, Sato K, Watanabe A, Ishii T, Itoh K, Yokoi T, Yoshizato K, Sugiyama Y, Suzuki H (2007) Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. Am J Physiol Gastrointest Liver Physiol 292:G1450-G1463
20. Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Takeda K, Utsunomiya H, Oda K, Warabi E, Ishii T, Osaka K, Hyodo I, Yamamoto M (2008) Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol 295:G735-G747
21. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007
22. Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D (2011) c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 4:ra19
23. Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X (2005) Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs 16:1009-1016
24. Shord SS, Thompson DM, Krempl GA, Hanigan MH (2006) Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs 17:207-215
25. Uwayama J, Hirayama A, Yanagawa T, Warabi E, Sugimoto R, Itoh K, Yamamoto M, Yoshida H, Koyama A, Ishii T (2006) Tissue Prx I in the protection against Fe-NTA and the reduction of nitroxyl radicals. Biochem Biophys Res Commun 339:226-231
26. Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE (1996) Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 73:610-614
27. Wood ZA, Schroder E, Robin Harris J, Poole LB (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28:32-40
28. Zhou H, Kato A, Miyaji T, Yasuda H, Fujigaki Y, Yamamoto T, Yonemura K, Takebayashi S, Mineta H, Hishida A (2006) Urinary marker for oxidative stress in kidneys in cisplatin-induced acute renal failure in rats. Nephrol Dial Transplant 21:616-623